Browse News
Filter News
Found 122 articles
-
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
12/21/2023
DMK Pharmaceuticals Corporation announces that it has regained the full rights to commercialize ZIMHI ® (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC.
-
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate UpdateNow seeking out license opportunities for SYMJEPI®
11/28/2023
DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI® Injection 0.3mg and SYMJEPI® Injection 0.15mg products from USWM, LLC.
-
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/14/2023
DMK Pharmaceuticals Corporation today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate developments.
-
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
10/30/2023
DMK Pharmaceuticals Corporation today announced that the compensation committee of the board of directors approved the grant of a stock option on October 23, 2023, to purchase an aggregate of 70,000 shares of common stock to John W. Dorbin, Jr., a newly hired employee who was appointed as General Counsel and Corporate Secretary of the company.
-
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) - October 20, 2023
10/20/2023
DMK Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that the compensation committee of the board of directors approved the grant of a stock option on October 16, 2023, to purchase an aggregate of 151,416 shares of common stock to Seth A. Cohen, a newly hired employee who was appointed as Chief Financial Officer of the company.
-
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
10/19/2023
DMK Pharmaceuticals Corporation announced a series of management changes to optimize its leadership structure.
-
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
9/7/2023
Adamis Pharmaceuticals Corporation announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.
-
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/21/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
8/4/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
-
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
8/2/2023
Adamis Pharmaceuticals Corporation today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.
-
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
7/28/2023
Adamis Pharmaceuticals Corporation today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
-
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
6/26/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).
-
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
6/22/2023
Adamis Pharmaceuticals Corporation today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta.
-
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
5/25/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.
-
Adamis Pharmaceuticals Announces Reverse Stock Split - May 19, 2023
5/19/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.
-
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/15/2023
Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
5/8/2023
Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.
-
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
3/16/2023
Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
3/14/2023
Adamis Pharmaceuticals Corporation announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct offering.
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
3/14/2023
Adamis Pharmaceuticals Corporation announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update.